Amgen’s star PhIII osteoporosis drug romo slammed by surprising cardio risk, a big plus for rival Radius drug
Amgen’s romosozumab, one of its top late-stage drug prospects aimed at osteoporosis, is in some serious trouble.
Late Sunday the big biotech $AMGN and its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
